JAT announces distribution agreement with Healthy One
Jat Energy Limited (ASX:JAT) today announced it has entered into a distribution agreement with Healthy One Co., Ltd (H1). H1 is a subsidiary of Hong Kong listed Tian Ge Interactive Holdings Ltd (HKSE code:1980).
H1 has been growing its online and offline distribution capacity in China for eight years. The key terms of the agreement are as follows.
- NEURIO Formulated Milk Powder With Lactoferrin
- Other Neurio brand products
- Other products supplied by JAT as agreed
H1 has non-exclusive rights to sell the products on the following platforms and channels.
(a) Cross-border platforms
- Tmall — H1 Overseas Products Speciality Store
- Taoanju Daigou Jinguan Store
- VIP (www.vip.com)
- Taobao shop distribution
(b) Offline retail outlets
- Hangzhou Tianjiong Industry Co., Ltd(c) Sales platforms
- Global Scanner
However it is an early stage of this company’s development and if considering this stock for your portfolio you should take all public information into account and seek professional financial advice.
The terms of the agreement state that payment must be made in full prior to product release, with an initial term of 12 months. The term can be extended upon H1 giving at least two months written notice before the end of the term.
Following the receipt of notice, both companies will commence negotiations in good faith to determine the terms and conditions of the agreement for the extended term. There are no conditions precedent in the agreement.
First order placed
Promisingly, H1 has already placed and paid for its first order under the agreement. The order consists of one pallet (960 tins) of NEURIO Formulated Milk Powder With Lactoferrin.
This news follows JAT’s announcement earlier this week, that Golden Koala Group Pty Ltd — 51% owned subsidiary of JAT — had entered into a supply agreement with AustAgri Pty Limited. Under the agreement, Golden Koala are set to supply its Golden Koala Premium Range Infant Formulas to AustAgri for sale in mainland China, Hong Kong, Macau and Taiwan, as well as via e-commerce platforms.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.